Cancer Research Cell Death Mechanisms and Cancer Therapy Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Towle, M. J.
Right arrow Articles by Littlefield, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Towle, M. J.
Right arrow Articles by Littlefield, B. A.
[Cancer Research 61, 1013-1021, February 1, 2001]
© 2001 American Association for Cancer Research

Experimental Therapeutics

In Vitro and In Vivo Anticancer Activities of Synthetic Macrocyclic Ketone Analogues of Halichondrin B1

Murray J. Towle, Kathleen A. Salvato, Jacqueline Budrow, Bruce F. Wels, Galina Kuznetsov, Kimberley K. Aalfs, Susan Welsh, Wanjun Zheng, Boris M. Seletsky, Monica H. Palme, Gregory J. Habgood, Lori A. Singer, Lucian V. DiPietro, Yuan Wang, Jack J. Chen, David A. Quincy, Ashley Davis, Kentaro Yoshimatsu, Yoshito Kishi, Melvin J. Yu and Bruce A. Littlefield2

Departments of Anticancer Research [M. J. T., K. A. S., J. B., B. F. W., G. K., K. K. A., S. W., B. A. L.] and Medicinal Chemistry [W. Z., B. M. S., M. H. P., G. J. H., L. A. S., L. V. D., Y. W., J. J. C., D. A. Q., M. J. Y.] and Advisory Board [Y. K.], Eisai Research Institute, Andover, Massachusetts 01810; Cytoskeleton, Incorporated, Denver, Colorado 80206 [A. D.]; and Discovery Research Laboratories II, Tsukuba Research Laboratories, Eisai Company, Limited, Tsukuba-shi, Ibaraki 300-26, Japan [K. Y.]

Halichondrin B is a highly potent anticancer agent originally found in marine sponges. Although scarcity of the natural product has hampered efforts to develop halichondrin B as a new anticancer drug, the existence of a complete synthetic route has allowed synthesis of structurally simpler analogues that retain the remarkable potency of the parent compound. In this study, we show that two macrocyclic ketone analogues of halichondrin B, ER-076349 and ER-086526, have sub-nM growth inhibitory activities in vitro against numerous human cancer cell lines as well as marked in vivo activities at 0.1–1 mg/kg against four human xenografts: MDA-MB-435 breast cancer, COLO 205 colon cancer, LOX melanoma, and NIH:OVCAR-3 ovarian cancer. ER-076349 and ER-086526 induce G2-M cell cycle arrest and disruption of mitotic spindles, consistent with the tubulin-based antimitotic mechanism of halichondrin B. This is supported further by direct binding of the biotinylated analogue ER-040798 to tubulin and inhibition of tubulin polymerization in vitro by ER-076349 and ER-086526. Retention of the extraordinary in vitro and in vivo activity of halichondrin B in structurally simplified, fully synthetic analogues establishes the feasibility of developing halichondrin B-based agents as highly effective, novel anticancer drugs.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
G. Kuznetsov, K. TenDyke, M. J. Towle, H. Cheng, J. Liu, J. P. Marsh, S. E.R. Schiller, M. R. Spyvee, H. Yang, B. M. Seletsky, et al.
Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin
Mol. Cancer Ther., October 1, 2009; 8(10): 2852 - 2860.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. T. Vahdat, B. Pruitt, C. J. Fabian, R. R. Rivera, D. A. Smith, E. Tan-Chiu, J. Wright, A. R. Tan, N. A. DaCosta, E. Chuang, et al.
Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
J. Clin. Oncol., June 20, 2009; 27(18): 2954 - 2961.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Goel, A. C. Mita, M. Mita, E. K. Rowinsky, Q. S. Chu, N. Wong, C. Desjardins, F. Fang, M. Jansen, D. E. Shuster, et al.
A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies
Clin. Cancer Res., June 15, 2009; 15(12): 4207 - 4212.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. R. Tan, E. H. Rubin, D. C. Walton, D. E. Shuster, Y. N. Wong, F. Fang, S. Ashworth, and L. S. Rosen
Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors
Clin. Cancer Res., June 15, 2009; 15(12): 4213 - 4219.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
G. Kuznetsov, Q. Xu, L. Rudolph-Owen, K. TenDyke, J. Liu, M. Towle, N. Zhao, J. Marsh, S. Agoulnik, N. Twine, et al.
Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A
Mol. Cancer Ther., May 1, 2009; 8(5): 1250 - 1260.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Okouneva, O. Azarenko, L. Wilson, B. A. Littlefield, and M. A. Jordan
Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase
Mol. Cancer Ther., July 1, 2008; 7(7): 2003 - 2011.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
D. A. Dabydeen, J. C. Burnett, R. Bai, P. Verdier-Pinard, S. J. H. Hickford, G. R. Pettit, J. W. Blunt, M. H. G. Munro, R. Gussio, and E. Hamel
Comparison of the Activities of the Truncated Halichondrin B Analog NSC 707389 (E7389) with Those of the Parent Compound and a Proposed Binding Site on Tubulin
Mol. Pharmacol., December 1, 2006; 70(6): 1866 - 1875.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
M. J. Yu, B. A. Littlefield, F. G. Fang, J. Orr, N. Wong, M. D. Lewis, S. L. Silberman, and Y. Kishi
Discovery of E7389: Chemistry Strategy and Material Supply Challenges
Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 225 - 229.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
T.-C. Chou, H. Dong, X. Zhang, W. P. Tong, and S. J. Danishefsky
Therapeutic Cure against Human Tumor Xenografts in Nude Mice by a Microtubule Stabilization Agent, Fludelone, via Parenteral or Oral Route
Cancer Res., October 15, 2005; 65(20): 9445 - 9454.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. A. Jordan, K. Kamath, T. Manna, T. Okouneva, H. P. Miller, C. Davis, B. A. Littlefield, and L. Wilson
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth
Mol. Cancer Ther., July 1, 2005; 4(7): 1086 - 1095.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. L. Simmons, E. Andrianasolo, K. McPhail, P. Flatt, and W. H. Gerwick
Marine natural products as anticancer drugs
Mol. Cancer Ther., February 1, 2005; 4(2): 333 - 342.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Kuznetsov, M. J. Towle, H. Cheng, T. Kawamura, K. TenDyke, D. Liu, Y. Kishi, M. J. Yu, and B. A. Littlefield
Induction of Morphological and Biochemical Apoptosis following Prolonged Mitotic Blockage by Halichondrin B Macrocyclic Ketone Analog E7389
Cancer Res., August 15, 2004; 64(16): 5760 - 5766.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Goodin, M. P. Kane, and E. H. Rubin
Epothilones: Mechanism of Action and Biologic Activity
J. Clin. Oncol., May 15, 2004; 22(10): 2015 - 2025.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. L. Amador, J. Jimeno, L. Paz-Ares, H. Cortes-Funes, and M. Hidalgo
Progress in the development and acquisition of anticancer agents from marine sources
Ann. Onc., November 1, 2003; 14(11): 1607 - 1615.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.